LOXL2 and fibrosis: In this respect, therapeutic inhibition of extracellular LOXL2 activity in livers with preestablished fibrosis interferes with collagen packaging, rendering it more accessible to infiltrating Ly6Chi monocyte-derived MoMFs, which uniquely bring to the fibrotic scar a set of membrane-bound and secreted collagen- and elastin-degrading enzymes.